2020
DOI: 10.7150/ijms.49983
|View full text |Cite
|
Sign up to set email alerts
|

Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia

Abstract: Background: Acute myeloid leukemia (AML) is a malignant hematological disease with high refractory rate. Immune escape of AML cells is one of the underlying mechanisms mediating the relapse of the cancers. Various immunotherapies based on the 'patients' immune response to tumor cells have been developed to targeting the immune escape of AML cells, which lead to the minimal residual disease (MRD) after treatment. But the efficacy of those treatments or the combination of treatments remains unsatisfactory. Metho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 44 publications
0
2
0
Order By: Relevance
“…Their use with TLR agonists shows an enhanced antitumor effect. The main mechanism to achieve this is through the stimulation of tumor CTL [ 141 , 142 ]. A synergistic effect was observed when combining TLR agonists with monoclonal antibodies [ 143 , 144 ] and inhibitors of cell-cycle-regulating pathways [ 145 ].…”
Section: Tlr Agonists As Future Targets In Cancer Therapymentioning
confidence: 99%
“…Their use with TLR agonists shows an enhanced antitumor effect. The main mechanism to achieve this is through the stimulation of tumor CTL [ 141 , 142 ]. A synergistic effect was observed when combining TLR agonists with monoclonal antibodies [ 143 , 144 ] and inhibitors of cell-cycle-regulating pathways [ 145 ].…”
Section: Tlr Agonists As Future Targets In Cancer Therapymentioning
confidence: 99%
“…(127) TLR7/8 agonists have been shown to activate NF-κB-mediated proinflammatory cytokine and chemokine expression, which can enhance the immune response to cancer-specific antigens. Several strategies to enhance antigen immunogenicity involving TLR7/8 agonists include direct linkage between TLR7/8 agonist and antigen (128)(129)(130), enhancing trafficking to draining lymph nodes, (94) and delivery of mRNA which serves as a TLR7 adjuvant and encodes for an antigen. (131) These systems can be used as either in one of two ways as prophylactics or therapeutics.…”
Section: Co-delivery With Cancer Vaccinesmentioning
confidence: 99%